Cheapest GLP-1 Medications 2026: Full Cost Comparison

At a glance: cheapest GLP-1 cost comparison (2026)

Option	Monthly cost (2026 sticker)	What's included	FDA-approved?
Compounded semaglutide (telehealth)	~$99–$199 + possible membership	Medication; support varies by provider	No
Wegovy oral pill (self-pay)	~$149	Medication only	Yes (weight management)
Foundayo (orforglipron) oral pill — LillyDirect	~$149 (starting dose)	Medication only	Yes (weight management)
Compounded tirzepatide (telehealth)	~$125–$399 + possible membership	Medication; support varies by provider	No
Nouri (compounded semaglutide / tirzepatide, all-in)	$120–$175/mo (6-month plan)	Medication + nutrition + fitness + clinician care, no separate membership	No
Wegovy injection (self-pay)	~$349	Medication only	Yes (weight management)
Ozempic (self-pay)	~$349	Medication only	Yes (type 2 diabetes)
Zepbound vials — LillyDirect	~$299–$449	Medication only	Yes (weight management)
Mounjaro (no self-pay discount program)	~$1,000+	Medication only	Yes (type 2 diabetes)

Prices above are self-pay/cash figures reflecting publicly available information as of July 2026 from manufacturer and pharmacy websites — verify current figures before deciding. With a manufacturer savings card, a patient-assistance program, or Medicare's $50 Bridge, eligible patients pay far less (see below). Compounded competitor prices are market ranges; Nouri's figures are its published rates. See Nouri's GLP-1 telehealth pricing dataset for compiled market data.

The cheapest legitimate way to get a GLP-1 in 2026, ranked

"Cheapest" depends entirely on your insurance and eligibility. Ranked from lowest real cost to highest, the legitimate routes in 2026 are:

1. $0 — manufacturer patient-assistance programs (PAPs). Novo Nordisk's and Eli Lilly's assistance programs provide brand-name GLP-1s at no cost to patients who meet income limits (often up to about 400% of the federal poverty level) and lack adequate coverage. This is the true floor if you qualify.
2. ~$25/month — manufacturer savings cards. If you have commercial insurance that covers the drug, NovoCare and LillyDirect savings cards can drop your copay to roughly $25/month. They do not work with Medicare or Medicaid.
3. $50/month — the Medicare GLP-1 Bridge. Eligible Medicare Part D members pay a flat $50/month for covered GLP-1s from July 1, 2026 through Dec 31, 2027 (eligibility below).
4. ~$149/month — brand oral pills, self-pay. Foundayo (orforglipron) and oral Wegovy start around $149/month at their lower doses through LillyDirect and NovoCare — the cheapest FDA-approved route without insurance.
5. ~$299–$449/month — brand injection, self-pay. Zepbound single-dose vials through LillyDirect are the cheapest self-pay injectable.
6. ~$99–$349/month (advertised) — compounded semaglutide or tirzepatide. Often the lowest sticker price, but not FDA-approved, and the market has tightened sharply in 2026 (see below). Verify the all-in cost and the pharmacy before you judge it on price alone.

The rest of this guide breaks down each route, what it really costs all-in, and how to tell a legitimate program from one to avoid.

Why GLP-1 prices span such a wide range

GLP-1 receptor agonists — semaglutide and tirzepatide are the two active molecules in this class — come from two structurally different supply chains in 2026, and those chains explain most of the price variation.

Brand-name, FDA-approved drugs (Wegovy, Ozempic, Zepbound, Mounjaro) are manufactured by Novo Nordisk and Eli Lilly, sold through retail pharmacies, and listed at prices that often exceed $1,000/month without insurance. Manufacturer self-pay savings programs — NovoCare for Wegovy, LillyDirect for Zepbound — bring those figures down substantially, to approximately $149–$449 depending on the form and program. These drugs went through FDA's full approval process, supported by large clinical trials of the branded molecules: semaglutide's weight-management indication is based on the STEP-1 trial (Wilding et al., NEJM, 2021), tirzepatide's by SURMOUNT-1 (Jastreboff et al., NEJM, 2022). Those trials studied the FDA-approved branded drugs, not compounded versions.

Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies (503A or 503B under federal law) using active pharmaceutical ingredients. They are not FDA-approved, and the FDA does not evaluate compounded products for safety, efficacy, or quality in the same way it does brand-name drugs. They are legal when prescribed by a licensed provider for a patient's individual clinical needs. Because compounding pharmacies source ingredients directly without brand-name R&D recovery costs, the price is substantially lower — but the regulatory protections also differ. FDA's compounding overview explains those differences in detail.

Within the compounded category, prices vary further based on what's included: some programs charge for medication only; others bundle clinician consultations, nutrition coaching, or care coordination — either within the medication price or as a separate mandatory membership.

Sticker price vs. all-in cost: why the cheapest headline isn't always the cheapest program

The most common source of confusion in this market is the gap between the advertised "medication price" and the real monthly cost. Many "$99/month" compounded GLP-1 programs add a separate mandatory membership fee of $49–$79/month covering consultations, messaging, or the care platform. The medication is $99; the total charge to your card is $148–$178.

That is not inherently a bad structure — clinical support and behavioral guidance have real value, especially for a treatment that works best alongside dietary and lifestyle changes. But when comparing programs, you need one number: the all-in monthly cost, including every mandatory recurring charge.

Questions to ask any provider before signing up:

• Is there a separate membership or platform fee? Is it optional or mandatory?
• Is the initial consultation included, or billed separately?
• Does the price change at higher doses, or stay flat?
• Are follow-up clinician check-ins included, or charged per visit?

What each type of program actually includes is what separates a low sticker from a low all-in cost — the sections below break that down route by route.

Brand self-pay options in 2026: what each drug costs

All four brand-name GLP-1 drugs have self-pay mechanisms in 2026, but the programs and prices vary considerably.

Wegovy (semaglutide, FDA-approved for weight management)

Novo Nordisk's NovoCare program offers self-pay pricing for Wegovy. As of July 2026, the Wegovy injection pen is about $349/month (roughly $199/month for the first two fills for new self-pay patients), and the oral Wegovy tablet runs about $149/month at its 1.5 mg and 4 mg maintenance doses — the 4 mg $149 rate is a limited-time offer through Aug 31, 2026. These figures are dose- and time-dependent; confirm current pricing at NovoCare's Wegovy cost page before deciding.

Foundayo (orforglipron, FDA-approved for weight management)

Foundayo is Eli Lilly's once-daily oral GLP-1 pill — the first with no food, water, or timing restrictions — FDA-approved on April 1, 2026 for chronic weight management (it is not yet approved for type 2 diabetes). Through LillyDirect it is priced by dose: about $149/month for the 0.8 mg starting dose, rising to roughly $199–$349/month at higher maintenance doses. Because it is a pill rather than an injection and starts near the bottom of the brand price range, it is now one of the cheapest FDA-approved routes for people paying cash.

Zepbound (tirzepatide, FDA-approved for weight management)

Eli Lilly sells Zepbound vials directly through LillyDirect at tiered prices: approximately $299/month (lower doses) to $449/month (higher doses), as of June 2026. Eligibility conditions apply — verify current tiers at LillyDirect.

Ozempic (semaglutide, FDA-approved for type 2 diabetes)

Ozempic is FDA-approved for type 2 diabetes management, not for weight loss, and is sometimes prescribed off-label for weight management. Without insurance, it typically runs approximately $349/month. Because it lacks an FDA weight-management indication, it is less common in commercial telehealth weight programs. For a full breakdown, see our guide to Ozempic cost without insurance.

Mounjaro (tirzepatide, FDA-approved for type 2 diabetes)

Mounjaro is FDA-approved for type 2 diabetes. Without insurance and without patient-assistance, it typically exceeds $1,000/month — there is no broad self-pay discount program comparable to LillyDirect's Zepbound vials.

For per-drug deep dives: Wegovy cost without insurance · Zepbound cost without insurance.

Manufacturer savings cards and patient assistance: the real $0–$25 floor

The lowest prices in this market are not compounded sticker prices — they are the manufacturer programs most cost comparisons skip.

• Savings cards (commercial insurance): If you have commercial insurance that covers a GLP-1, NovoCare (Wegovy) and LillyDirect (Zepbound, Foundayo) savings cards can reduce your out-of-pocket cost to roughly $25/month. They cannot be used with Medicare, Medicaid, or other government coverage.
• Patient-assistance programs (little or no coverage): Novo Nordisk's and Lilly's patient-assistance programs can provide brand-name medication at no cost to patients who meet income requirements — commonly up to about 400% of the federal poverty level — and who are uninsured or underinsured. Approval is not guaranteed and requires an application with income documentation.

If you qualify for either, a brand-name, FDA-approved GLP-1 is almost always cheaper than any compounded program. Start there before comparing sticker prices.

Pharmacy discount cards: GoodRx, Costco, and Amazon

For a drug you are paying cash for, a pharmacy discount card can beat the retail counter price:

• GoodRx / SingleCare: free coupons that can bring a $1,000+ retail GLP-1 down by a few hundred dollars at participating pharmacies. Discounts are largest on the diabetes drugs (Ozempic, Mounjaro), and they cannot be combined with insurance.
• Costco Member Prescription Program: often among the lowest cash counter prices, and available for pharmacy use even without a paid Costco membership in many states.
• Amazon Pharmacy: lists cash prices and sometimes applies manufacturer cash programs (for example, Zepbound vials) with home delivery.

Discount-card prices change constantly and vary by pharmacy and ZIP code — check two or three before filling.

Denied by insurance? How to appeal

Many commercial plans still exclude GLP-1 weight-loss drugs or require prior authorization — but a denial is not the end of the road, and the appeals process overturns a meaningful share of GLP-1 denials:

1. Ask your prescriber for a letter of medical necessity documenting your BMI, weight-related conditions, and prior weight-loss attempts.
2. Request a peer-to-peer review, where your clinician speaks directly with the insurer's medical reviewer.
3. File an internal appeal, then an external review. Under the Affordable Care Act you can escalate to an independent external reviewer whose decision is binding on the plan.

If coverage still fails, the self-pay routes above — savings cards, patient assistance, oral brand pills, or a transparent cash program — are the fallback.

Compounded GLP-1 programs: what drives the price range

Compounded semaglutide and tirzepatide are available from many telehealth platforms in 2026, with sticker prices ranging from roughly $99 to $399/month. That range reflects real differences in program structure:

• Plan length: Quarterly or semi-annual commitments typically reduce the per-month equivalent versus monthly billing cycles.
• Dose policy: Some providers charge the same price at any dose; others charge more as doses increase during titration. Ask explicitly how the cost changes when your provider adjusts your dose upward.
• What's bundled: Medication only, or medication plus nutrition guidance, fitness programming, and clinical check-ins?
• Pharmacy legitimacy: State-licensed 503A pharmacies prepare medications for individual patients; 503B outsourcing facilities prepare in larger volume batches. Not all telehealth providers name their compounding pharmacy — providers who do are easier to verify.

The FDA has published guidance on the risks of unapproved compounded GLP-1 products, including concerns about products sold without a legitimate prescription or from unverified sources. The NIDDK's overview of prescription obesity medications provides additional context on how these medications are prescribed and what the clinical eligibility criteria typically look like.

For a structured comparison of compounded and brand programs on cost, regulatory status, and access, see: compounded vs. brand GLP-1: a cost comparison. For medication-specific pricing, see semaglutide cost and tirzepatide cost without insurance.

Is compounded semaglutide still legal in 2026?

Yes — but the legal lane is narrower than it was, and many older guides describe a market that no longer exists. Here is the accurate 2026 picture:

• Because tirzepatide (Dec 2024) and semaglutide (Feb 2025) are no longer on the FDA drug-shortage list, the temporary shortage exemption that let pharmacies compound them at scale has ended.
• A 503A state-licensed pharmacy may still compound these medications for an individual patient with a valid prescription when a prescriber determines the patient needs a preparation that differs clinically from the commercial product. Compounding a straight copy of an FDA-approved drug is not permitted.
• 503B outsourcing facilities are being restricted further: in May 2026 the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-substance list.
• The FDA has also acted on marketing, issuing warning letters to roughly 30 telehealth companies in 2025 over false or misleading claims about compounded GLP-1s, and has warned about counterfeit products and dosing errors.

The practical takeaway for anyone shopping on price: the era of cheap, mass-marketed compounded "copies" is closing, so who you buy from now matters more than the sticker price. A legitimate program runs a real clinical evaluation, prescribes only when appropriate, and works with a named, state-licensed compounding pharmacy you can verify. Compounded GLP-1 medications remain not FDA-approved and are not therapeutically equivalent to the brand-name drugs.

Is cheap always safe? How to evaluate a provider

Markers of a legitimate program include: a real clinical evaluation before prescribing, a named and verifiable state-licensed 503A compounding pharmacy, transparent all-in pricing, and a telehealth certification from an organization like LegitScript, which verifies prescribing practices and pharmacy legitimacy.

Medicare and coverage options in 2026

Most insurance plans — including Medicare Part D — have historically excluded FDA-approved GLP-1 weight-loss drugs from coverage, though this is changing in some markets. Two notable 2026 developments:

• Medicare GLP-1 Bridge program: This CMS demonstration launched July 1, 2026 and runs through Dec 31, 2027, giving eligible Part D members a flat $50/month copay that does not rise with dose. Covered drugs are Wegovy (injection or tablet), the Zepbound KwikPen, and Foundayo. Eligibility is based on Part D enrollment, age 18+, and BMI thresholds (roughly BMI ≥35, or ≥30 with certain heart conditions, or ≥27 with prediabetes or a prior cardiovascular event); people already on a Part D GLP-1 or with type 2 diabetes are generally excluded, and the $50 does not count toward your deductible or out-of-pocket cap. See the CMS Medicare GLP-1 Bridge page for full criteria.
• Commercial insurance: Roughly 40% of commercial plans still exclude GLP-1 weight-loss drugs; prior authorization requirements are common among those that do cover them. For guidance on navigating insurance, see our guides: does insurance cover Wegovy and Zepbound? and how to get a GLP-1 covered by insurance.

Compounded GLP-1 programs like Nouri operate outside of insurance, with direct self-pay pricing. There is no insurance billing for Nouri's program.

FSA and HSA reimbursement

Compounded GLP-1 medications prescribed by a licensed provider as part of treatment for obesity or a related medical condition may be eligible for FSA or HSA reimbursement under IRC §213(d) as a qualified medical expense. Whether a specific plan will reimburse depends on the plan's terms — this is not universal. Nouri does not accept FSA/HSA cards directly at checkout; this would be a post-payment reimbursement submitted by the member. Confirm eligibility with your plan administrator and, for any tax question, a qualified tax professional. For a full breakdown, see our guide to using HSA/FSA for a GLP-1.

See what you'd pay with Nouri →
Compounded semaglutide from $120/mo and tirzepatide from $175/mo — all-in on the 6-month plan, with medication, nutrition, fitness, and clinician care included and no separate membership. Compounded GLP-1s are not FDA-approved and are not equivalent to the brand-name drugs. 5-minute assessment · The Nouri Promise: a full refund if you're not satisfied in your first 30 days, available on the 3-month and 6-month plans.

How to compare GLP-1 programs beyond sticker price

A practical checklist before you choose a program:

1. Get the all-in monthly number. Medication + mandatory membership + consultation + per-dose fees — one figure, not a menu.
2. Confirm the pharmacy is named and verifiable. A legitimate provider names a specific state-licensed 503A or 503B compounding pharmacy you can look up independently.
3. Ask how pricing changes as your dose increases. Some programs charge more at higher doses; others keep the price flat.
4. Understand what support is included. Medication-only programs put the behavioral and nutritional work entirely on you; bundled programs provide clinical guidance throughout.
5. Read the refund and cancellation terms. A legitimate program with a money-back guarantee states the material terms clearly — duration, eligibility, and how to claim.
6. Check for independent certification. LegitScript and similar certifications require verification of prescribing practices and pharmacy legitimacy; they are a meaningful signal of accountability.

For a current view of what programs across the telehealth market charge, see Nouri's GLP-1 telehealth pricing dataset on HuggingFace, which compiles publicly available pricing across providers. Our full GLP-1 cost guide for 2026 has the complete landscape.

Price is only one column. For the full side-by-side — fees, guarantees, pharmacy disclosure, and dose-price behavior — see the ranked comparison of compounded GLP-1 telehealth providers.

If tirzepatide specifically is the target, the cheapest compounded tirzepatide online breaks down what the lowest advertised prices actually include.

Frequently asked questions

What's the cheapest GLP-1 without insurance?

On sticker price, compounded semaglutide (~$99–$199/month) and the Wegovy oral pill (~$149) are typically the lowest-cost routes. Brand self-pay options run ~$299–$449 (Zepbound vials) and ~$349 (Wegovy injection). Always verify the all-in monthly cost — including any mandatory membership fee. Compounded GLP-1 medications are not FDA-approved.

What's the cheapest way to get semaglutide online?

Compounded semaglutide through a telehealth provider carries the lowest sticker price (~$99–$199/month), but many programs add a $49–$79 monthly membership on top. Brand self-pay (Wegovy ~$349 injection, ~$149 oral) is the FDA-approved route. Compounded semaglutide is not FDA-approved and not therapeutically equivalent to Wegovy or Ozempic. Compare all-in costs before choosing.

Which GLP-1 is cheapest — Ozempic, Wegovy, Zepbound, or compounded?

At self-pay rates: Wegovy injection and Ozempic are approximately $349/month, Zepbound vials $299–$449, Mounjaro $1,000+ with no broad cash discount program. Compounded semaglutide (~$99–$199 sticker) and tirzepatide (~$125–$399 sticker) are often lower on sticker price, but are not FDA-approved and the real all-in cost varies based on mandatory membership fees.

Is it safe to buy a GLP-1 online?

From a legitimate telehealth provider, yes. A legitimate program requires a clinician evaluation, names a state-licensed 503A or 503B pharmacy, and shows transparent pricing. The FDA has warned about counterfeit and adulterated compounded GLP-1 products. Avoid any provider that ships without a prescription, won't name their pharmacy, or claims their compounded product is FDA-approved or equivalent to a brand-name drug.

Does FSA or HSA cover compounded GLP-1?

Compounded GLP-1 medications prescribed for a qualifying medical condition may be eligible for FSA or HSA reimbursement under IRC §213(d). Eligibility depends on your specific plan. Nouri does not accept FSA/HSA cards directly — this would be post-payment reimbursement. Confirm with your plan administrator and a qualified tax professional before submitting a claim.

How low will GLP-1 prices go in 2026?

Brand self-pay prices have declined to approximately $149–$449/month depending on the drug and dosage form. The Medicare GLP-1 Bridge launched July 1, 2026, giving eligible Part D beneficiaries a flat $50/month copay through Dec 31, 2027. There is no U.S. generic for semaglutide or tirzepatide yet; significant retail price drops are not expected until after patent expiration, currently projected around 2032.

What is the cheapest GLP-1 pill?

The cheapest FDA-approved GLP-1 pills in 2026 are Foundayo (orforglipron) and oral Wegovy, each starting around $149/month self-pay at their lower doses. Rybelsus (oral semaglutide) is approved for type 2 diabetes and typically costs more without insurance. Compounded oral or sublingual semaglutide is sometimes advertised for less, but is not FDA-approved.

What BMI do I need to qualify for a GLP-1?

Clinical eligibility for weight-management GLP-1s generally starts at a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. A licensed clinician confirms eligibility, and not everyone who applies qualifies.

Is compounded semaglutide still legal in 2026?

Yes, in a narrower way than before. Since semaglutide and tirzepatide left the FDA shortage list (Feb 2025 and Dec 2024), they can no longer be mass-compounded under the shortage exemption. A state-licensed 503A pharmacy can still compound them for an individual patient with a valid prescription when clinically appropriate, but making straight copies of the approved drugs is not allowed, and the FDA has moved to further restrict 503B bulk compounding. Compounded GLP-1s are not FDA-approved.

How much is Ozempic with a GoodRx coupon or at Costco?

Ozempic's retail cash price is roughly $1,000/month, and a GoodRx or SingleCare coupon can bring it down by a few hundred dollars at participating pharmacies. Costco's member prescription program and Amazon Pharmacy sometimes list lower cash prices. Prices vary by pharmacy and ZIP code, so compare a few before filling, and note that coupons cannot be combined with insurance.

Who qualifies for the $50 Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge (July 1, 2026–Dec 31, 2027) offers a flat $50/month copay to Part D members who are 18 or older and meet BMI-based criteria — roughly BMI ≥35, or ≥30 with certain heart conditions, or ≥27 with prediabetes or a prior cardiovascular event. People already on a Part D GLP-1 or with type 2 diabetes are generally excluded. Covered drugs are Wegovy, the Zepbound KwikPen, and Foundayo.

What should I do if my insurance denies a GLP-1?

Ask your prescriber for a letter of medical necessity, request a peer-to-peer review, and if needed file an internal appeal followed by an external review — under the Affordable Care Act, an independent reviewer's decision is binding on the plan. If coverage still fails, manufacturer savings cards, patient-assistance programs, oral brand pills, or a transparent cash program are the fallback.

Sources & references

1. FDA: Human Drug Compounding — regulatory framework for 503A and 503B compounding pharmacies (U.S. Food & Drug Administration).
2. FDA: Postmarket Drug Safety — GLP-1 unapproved product concerns — FDA warnings on compounded GLP-1 products sold without a valid prescription or from unverified sources.
3. NIDDK: Prescription medications to treat overweight and obesity — National Institute of Diabetes and Digestive and Kidney Diseases overview of approved weight-management medications.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. — Registration trial of semaglutide (the active molecule in Wegovy) for weight management in adults; not a study of compounded semaglutide.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022. — Registration trial of tirzepatide (the active molecule in Zepbound) for weight management in adults; not a study of compounded tirzepatide.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023. — Cardiovascular outcomes trial of branded semaglutide in adults with obesity and established cardiovascular disease.
7. Wegovy self-pay pricing — NovoCare (as of June 2026). Re-verify before publishing.
8. Zepbound self-pay vials — LillyDirect (as of June 2026). Re-verify before publishing.
9. CMS: Medicare GLP-1 Bridge — $50/month program (launched July 1, 2026).
10. FDA: Policies for compounders as GLP-1 supply stabilizes — semaglutide and tirzepatide removed from the drug-shortage list; limits on compounding "essentially copies" of approved drugs.
11. FDA: Proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk-substance list (proposed May 2026) — re-verify final status.
12. Eli Lilly: FDA approves Foundayo (orforglipron), oral GLP-1 pill for weight management (April 1, 2026).
13. GoodRx: GLP-1 drug cost and savings guide (2026).
14. Nouri GLP-1 telehealth pricing dataset (HuggingFace, 2026) — compiled public pricing across GLP-1 telehealth providers.

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and regulatory guidance change.

Prices and coverage information described here reflect publicly available data as of June 2026 and change frequently — re-verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a qualified tax professional before making any decisions. This content is for general informational purposes only and does not constitute medical, financial, or tax advice. The clinical trial data cited (STEP-1, SURMOUNT-1, SELECT) are studies of FDA-approved branded molecules — Wegovy, Zepbound — and are not evidence of outcomes for Nouri's compounded medications or for any individual patient. Brand registrations: Ozempic®, Wegovy®, and Rybelsus® are trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Medication is prescribed only when clinically appropriate, after evaluation by a licensed provider. Not all applicants qualify. Individual results vary.